The University of Chicago Header Logo

Connection

Richard Koya to Proto-Oncogene Proteins B-raf

This is a "connection" page, showing publications Richard Koya has written about Proto-Oncogene Proteins B-raf.
Connection Strength

1.508
  1. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
    View in: PubMed
    Score: 0.358
  2. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015 May 05; 15:356.
    View in: PubMed
    Score: 0.109
  3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41.
    View in: PubMed
    Score: 0.108
  4. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56.
    View in: PubMed
    Score: 0.107
  5. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
    View in: PubMed
    Score: 0.099
  6. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
    View in: PubMed
    Score: 0.099
  7. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
    View in: PubMed
    Score: 0.094
  8. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24.
    View in: PubMed
    Score: 0.088
  9. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
    View in: PubMed
    Score: 0.088
  10. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
    View in: PubMed
    Score: 0.087
  11. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.
    View in: PubMed
    Score: 0.081
  12. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.
    View in: PubMed
    Score: 0.080
  13. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39.
    View in: PubMed
    Score: 0.077
  14. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.